Elstree-BN

Phase 1Completed
0 watching 0 views this week💤 Quiet
30
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Smallpox

Conditions

Smallpox

Trial Timeline

Sep 1, 2003 → Feb 1, 2006

About Elstree-BN

Elstree-BN is a phase 1 stage product being developed by Bavarian Nordic for Smallpox. The current trial status is completed. This product is registered under clinical trial identifier NCT00189969. Target conditions include Smallpox.

Hype Score Breakdown

Clinical
10
Activity
5
Company
7
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT00189969Phase 1Completed

Competing Products

20 competing products in Smallpox

See all competitors
ProductCompanyStageHype Score
Smallpox vaccine, LISTER strain, from chick embryo cellsSanofiPhase 2
51
MVA (smallpox vaccine)SanofiPhase 1
32
ACAM3000 MVA VaccineSanofiPhase 1
32
MVA Smallpox vaccine + PlaceboSanofiPhase 2
51
ACAM1000 + vaccinia virus (calf lymph) smallpox vaccine: DryvaxSanofiPhase 2
51
IMVAMUNE (MVA-BN)Bavarian NordicPhase 2
49
MVA-BNBavarian NordicPhase 1
30
IMVAMUNE®Bavarian NordicPhase 2
49
LF formulation of IMVAMUNE® + FD formulation of IMVAMUNE®Bavarian NordicPhase 2
49
IMVAMUNE + IMVAMUNEBavarian NordicPhase 2
49
FD MVA-BNBavarian NordicPhase 3
74
IMVAMUNE®Bavarian NordicPhase 3
74
IMVAMUNE + IMVAMUNEBavarian NordicPhase 2
49
MVA-BN® (IMVAMUNE) + PlaceboBavarian NordicPhase 2
49
ACAM2000Emergent BioSolutionsPhase 3
69
VIGIVEmergent BioSolutionsPre-clinical
15
ACAM2000® smallpox vaccineEmergent BioSolutionsPre-clinical
15
BrincidofovirEmergent BioSolutionsPhase 1
25
Vaccination with ACAM2000Emergent BioSolutionsApproved
77
ACAM2000 Smallpox Vaccine + Vaccinia virus (calf lymph) smallpox vaccine: Dryvax®Emergent BioSolutionsPhase 2
44